Dillon & Associates Inc Pacira Bio Sciences, Inc. Transaction History

Dillon & Associates Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$30.68 - $40.09 $221,018 - $288,808	-7,204 Reduced 48.18%	7,749 $240,000
Q2 2023 Aug 08, 2023	SELL	$36.12 - $47.5 $965,668 - $1.27 Million	-26,735 Reduced 64.13%	14,953 $598,000
Q1 2023 May 02, 2023	BUY	$35.53 - $43.38 $1.48 Million - $1.81 Million	41,688 New	41,688 $1.71 Million
Q4 2022 Feb 06, 2023	SELL	$38.19 - $57.45 $55,757 - $83,877	-1,460 Reduced 3.37%	41,918 $1.64 Million
Q3 2022 Nov 08, 2022	BUY	$51.24 - $58.89 $591,002 - $679,237	11,534 Added 36.22%	43,378 $2.3 Million
Q2 2022 Jul 26, 2022	BUY	$51.49 - $81.64 $1.48 Million - $2.35 Million	28,759 Added 932.22%	31,844 $1.85 Million
Q1 2022 May 06, 2022	BUY	$60.03 - $76.49 $185,192 - $235,971	3,085 New	3,085 $234,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Dillon & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Dillon & Associates Inc with notifications on news.